Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Uttar Pradesh News: Deputy CM Keshav Prasad Maurya Mocks Akhilesh Yadav Over ‘Laddus’ Remark; Says SP Won’t Return To Power Till 2047
UP Voter Roll Cleanup: EC Orders Re-Verification Of 3 Crore Names Flagged As Ineligible Under Special Revision Drive
Mumbai Police Seize ₹679 Crore Drugs In 10 Months; 1,195 Arrested & 1,602 Kg Narcotics Confiscated
ED Searches Pune, Baramati Premises In ₹108 -Crore Dairy Investment Fraud Case
